Get the Stockscreener App
0.85
37.50%
-0.51
After Hours:
.87
0.02
+2.35%
Tenaya Therapeutics Inc stock is traded at $0.85, with a volume of 66.49M.
It is down -37.50% in the last 24 hours and down -44.81% over the past month.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
See More
Previous Close:
$1.36
Open:
$1.05
24h Volume:
66.49M
Relative Volume:
15.10
Market Cap:
$141.53M
Revenue:
-
Net Income/Loss:
$-111.13M
P/E Ratio:
-0.6439
EPS:
-1.32
Net Cash Flow:
$-91.53M
1W Performance:
-39.72%
1M Performance:
-44.81%
6M Performance:
+41.48%
1Y Performance:
-69.09%
1-Day Range:
$0.785
$1.05
1-Week Range:
$0.785
$1.46
52-Week Range:
$0.36
$2.945
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Name
Tenaya Therapeutics Inc
Sector
Industry
Phone
415-865-2066
Address
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.85 | 226.45M | 0 | -111.13M | -91.53M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-24 | Initiated | William Blair | Outperform |
| Nov-30-23 | Initiated | Leerink Partners | Outperform |
| Jun-15-22 | Initiated | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Stock (TNYA) Latest News
Tenaya Therapeutics (NASDAQ:TNYA) Given New $3.00 Price Target at HC Wainwright - MarketBeat
Chardan Capital Lowers Tenaya Therapeutics (NASDAQ:TNYA) Price Target to $8.00 - MarketBeat
Chardan Capital Maintains Tenaya Therapeutics (TNYA) Buy Recommendation - Nasdaq
HC Wainwright & Co. Maintains Tenaya Therapeutics (TNYA) Buy Recommendation - Nasdaq
Pharma News: Will Tenaya Therapeutics Inc stock remain a Wall Street favorite2025 Market Sentiment & Weekly Return Optimization Plans - moha.gov.vn
Tenaya Stock Drops After Announcing $60M Equity OfferingTenaya Therapeutics (NASDAQ:TNYA) - Benzinga
Tenaya Therapeutics (TNYA) Price Target Lowered by HC Wainwright & Co. | TNYA Stock News - GuruFocus
Tenaya Therapeutics slumps after $60 million share sale - TradingView — Track All Markets
Tenaya Therapeutics Prices 50 Mln Unit Offering At $60 Mln, Clinical Hold Lifted On TN-201 - Nasdaq
Tenaya Therapeutics announces positive data from Phase 1b/2 trial - Traders Union
TNYA: Chardan Capital Lowers Price Target While Maintaining Buy Rating | TNYA Stock News - GuruFocus
Tenaya Therapeutics Prices $60 Million Unit Offering - marketscreener.com
Tenaya Therapeutics prices $60 million public offering of stock and warrants - Investing.com Nigeria
Tenaya Therapeutics Announces Pricing of Public Offering - The Manila Times
Tenaya Therapeutics Announces Pricing of Public Offering | Associated Press | syndication news - Enidnews.com
Tenaya Therapeutics (TNYA) prices $60M public unit sale of 50,000,000 units - Stock Titan
Tenaya Therapeutics Says FDA Hold Removed on TN-201, Posts Positive TN-401 Interim Data, Plans Stock, Warrant Offering - marketscreener.com
Tenaya Therapeutics slides after launching stock offering - TradingView — Track All Markets
Tenaya Therapeutics plans to offer stock and warrant units By Investing.com - Investing.com Canada
Tenaya Therapeutics plans to offer stock and warrant units - Investing.com
FDA lifts clinical hold on Tenaya’s heart disease gene therapy trial - Investing.com Nigeria
Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy - Investing News Network
Tenaya Therapeutics stock falls on proposed share and warrant offering - Investing.com
Tenaya Therapeutics stock falls on proposed share and warrant offering By Investing.com - Investing.com UK
Tenaya Therapeutics says early trial shows promise for gene therapy in rare heart condition - marketscreener.com
Tenaya Therapeutics (Nasdaq: TNYA) proposes unit offering of common stock and warrants - Stock Titan
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical ... - Bakersfield.com
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC - The Manila Times
Tenaya Therapeutics Announces Proposed Public Offering - GlobeNewswire
Tenaya Therapeutics Reports Positive Interim Data from - GlobeNewswire
Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) Path To Profitability - simplywall.st
Tenaya Therapeutics Inc. (TNYA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Earnings Beat: Will Tenaya Therapeutics Inc. stock outperform growth indexesJuly 2025 Price Swings & AI Driven Stock Movement Reports - moha.gov.vn
Will Tenaya Therapeutics Inc. stock benefit from sector rotationJuly 2025 Snapshot & Stepwise Entry/Exit Trade Alerts - Newser
Why Tenaya Therapeutics Inc. stock is considered a top pick2025 Momentum Check & High Accuracy Swing Trade Signals - Newser
Tenaya Therapeutics: Risky But Promising Cardiac Gene Platform - Seeking Alpha
Can Tenaya Therapeutics Inc. stock resist market sell offs2025 Top Gainers & High Conviction Investment Ideas - Newser
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Will Tenaya Therapeutics Inc. stock return to pre crisis levelsEarnings Overview Report & Safe Entry Point Identification - Newser
Tenaya Therapeutics (TNYA) Stock Analysis Report | Financials & Insights - Benzinga
Is Tenaya Therapeutics Inc. stock attractive for hedge fundsMarket Movers & Expert Approved Trade Ideas - BỘ NỘI VỤ
Top 3 Insider Stock Buys in March-Are They Still Good in April? - MSN
How geopolitical tensions affect Tenaya Therapeutics Inc. stockJuly 2025 Spike Watch & Low Risk Profit Maximizing Plans - newser.com
Will Tenaya Therapeutics (NASDAQ:TNYA) Spend Its Cash Wisely? - Yahoo Finance
How supply chain issues affect Tenaya Therapeutics Inc. stock - newser.com
How resilient is Tenaya Therapeutics Inc. stock in market downturnsIPO Watch & Weekly Watchlist for Hot Stocks - newser.com
Should you wait for a breakout in Tenaya Therapeutics Inc.Breakout Watch & Safe Capital Investment Plans - newser.com
Tenaya Therapeutics SVP, finance Higa sells $1.8k in stock By Investing.com - Investing.com Australia
Tenaya therapeutics CEO Ali Faraz sells $4,157 in stock By Investing.com - Investing.com Nigeria
Tenaya Therapeutics Inc Stock (TNYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):